Starpharma Holdings Limited (SPHRF)
USD 0.06
(7.53%)
USD 0.06
(7.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 8.69 Million AUD | -49.64% |
| 2023 | 17.27 Million AUD | -2.87% |
| 2022 | 17.78 Million AUD | 62.57% |
| 2021 | 10.93 Million AUD | 41.1% |
| 2020 | 7.75 Million AUD | 19.93% |
| 2019 | 6.46 Million AUD | 23.5% |
| 2018 | 5.23 Million AUD | -6.65% |
| 2017 | 5.6 Million AUD | -41.68% |
| 2016 | 9.61 Million AUD | 40.88% |
| 2015 | 6.82 Million AUD | 74.51% |
| 2014 | 3.91 Million AUD | 51.47% |
| 2013 | 2.58 Million AUD | -54.03% |
| 2012 | 5.61 Million AUD | 165.7% |
| 2011 | 2.11 Million AUD | -22.37% |
| 2010 | 2.72 Million AUD | -18.67% |
| 2009 | 3.34 Million AUD | -21.59% |
| 2008 | 4.27 Million AUD | -9.14% |
| 2007 | 4.69 Million AUD | 27.11% |
| 2006 | 3.69 Million AUD | 45.91% |
| 2005 | 2.53 Million AUD | 182.02% |
| 2004 | 898.44 Thousand AUD | -38.98% |
| 2003 | 1.47 Million AUD | -7.58% |
| 2002 | 1.59 Million AUD | 43.55% |
| 2001 | 1.1 Million AUD | 456.9% |
| 2000 | 199.28 Thousand AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 8.69 Million AUD | -8.26% |
| 2024 Q4 | 8.69 Million AUD | 0.0% |
| 2024 FY | 8.69 Million AUD | -49.64% |
| 2024 Q1 | 9.48 Million AUD | -46.68% |
| 2024 Q2 | 9.48 Million AUD | 0.0% |
| 2023 Q1 | 16.62 Million AUD | -6.5% |
| 2023 FY | 17.27 Million AUD | -2.87% |
| 2023 Q4 | 17.78 Million AUD | 2.96% |
| 2023 Q3 | 17.27 Million AUD | 3.88% |
| 2023 Q2 | 16.62 Million AUD | 0.0% |
| 2022 FY | 17.78 Million AUD | 62.57% |
| 2022 Q4 | 17.78 Million AUD | 0.0% |
| 2022 Q2 | 12.24 Million AUD | 0.0% |
| 2022 Q3 | 17.78 Million AUD | 45.23% |
| 2022 Q1 | 12.24 Million AUD | 11.94% |
| 2021 Q2 | 8.23 Million AUD | 0.0% |
| 2021 Q1 | 8.23 Million AUD | 6.17% |
| 2021 Q3 | 10.93 Million AUD | 32.9% |
| 2021 Q4 | 10.93 Million AUD | 0.0% |
| 2021 FY | 10.93 Million AUD | 41.1% |
| 2020 Q2 | 8.59 Million AUD | 0.0% |
| 2020 Q1 | 8.59 Million AUD | 32.91% |
| 2020 FY | 7.75 Million AUD | 19.93% |
| 2020 Q4 | 7.75 Million AUD | 0.0% |
| 2020 Q3 | 7.75 Million AUD | -9.77% |
| 2019 Q1 | 4.29 Million AUD | -17.98% |
| 2019 FY | 6.46 Million AUD | 23.5% |
| 2019 Q2 | 4.29 Million AUD | 0.0% |
| 2019 Q3 | 6.42 Million AUD | 49.69% |
| 2019 Q4 | 6.46 Million AUD | 0.59% |
| 2018 Q2 | 4.93 Million AUD | 0.0% |
| 2018 FY | 5.23 Million AUD | -6.65% |
| 2018 Q4 | 5.23 Million AUD | 0.0% |
| 2018 Q1 | 4.93 Million AUD | -12.06% |
| 2018 Q3 | 5.23 Million AUD | 6.14% |
| 2017 Q3 | 5.6 Million AUD | 6.58% |
| 2017 FY | 5.6 Million AUD | -41.68% |
| 2017 Q1 | 5.26 Million AUD | -45.28% |
| 2017 Q2 | 5.26 Million AUD | 0.0% |
| 2017 Q4 | 5.6 Million AUD | 0.0% |
| 2016 Q1 | 6.95 Million AUD | 1.96% |
| 2016 Q4 | 9.61 Million AUD | 0.42% |
| 2016 Q2 | 6.95 Million AUD | 0.0% |
| 2016 Q3 | 9.57 Million AUD | 37.59% |
| 2016 FY | 9.61 Million AUD | 40.88% |
| 2015 FY | 6.82 Million AUD | 74.51% |
| 2015 Q2 | 4.09 Million AUD | 0.0% |
| 2015 Q4 | 6.82 Million AUD | 0.0% |
| 2015 Q3 | 6.82 Million AUD | 66.63% |
| 2015 Q1 | 4.09 Million AUD | 4.73% |
| 2014 Q3 | 3.91 Million AUD | 18.95% |
| 2014 Q1 | 3.28 Million AUD | 27.34% |
| 2014 FY | 3.91 Million AUD | 51.47% |
| 2014 Q4 | 3.91 Million AUD | 0.0% |
| 2014 Q2 | 3.28 Million AUD | 0.0% |
| 2013 Q3 | 2.58 Million AUD | -18.01% |
| 2013 Q4 | 2.58 Million AUD | 0.0% |
| 2013 FY | 2.58 Million AUD | -54.03% |
| 2013 Q1 | 3.14 Million AUD | -43.94% |
| 2013 Q2 | 3.14 Million AUD | 0.0% |
| 2012 FY | 5.61 Million AUD | 165.7% |
| 2012 Q4 | 5.61 Million AUD | 0.0% |
| 2011 FY | 2.11 Million AUD | -22.37% |
| 2011 Q4 | 2.11 Million AUD | 0.0% |
| 2010 Q4 | 2.72 Million AUD | 0.0% |
| 2010 FY | 2.72 Million AUD | -18.67% |
| 2009 Q4 | 3.34 Million AUD | 0.0% |
| 2009 FY | 3.34 Million AUD | -21.59% |
| 2008 FY | 4.27 Million AUD | -9.14% |
| 2008 Q4 | 4.27 Million AUD | 0.0% |
| 2007 FY | 4.69 Million AUD | 27.11% |
| 2007 Q4 | 4.69 Million AUD | 0.0% |
| 2006 Q4 | 3.69 Million AUD | 0.0% |
| 2006 FY | 3.69 Million AUD | 45.91% |
| 2005 FY | 2.53 Million AUD | 182.02% |
| 2005 Q4 | 2.53 Million AUD | 0.0% |
| 2004 Q4 | 898.44 Thousand AUD | 0.0% |
| 2004 FY | 898.44 Thousand AUD | -38.98% |
| 2003 FY | 1.47 Million AUD | -7.58% |
| 2003 Q4 | 1.47 Million AUD | 0.0% |
| 2002 FY | 1.59 Million AUD | 43.55% |
| 2002 Q4 | 1.59 Million AUD | 0.0% |
| 2001 FY | 1.1 Million AUD | 456.9% |
| 2001 Q4 | 1.1 Million AUD | 0.0% |
| 2000 FY | 199.28 Thousand AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -167.672% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 83.683% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1963.25% |
| SQZ Biotechnologies Company | 50.03 Million USD | 82.618% |
| Intellipharmaceutics International Inc. | 12 Million USD | 27.57% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 87.998% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 85.261% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -125.839% |
| Marizyme, Inc. | 26.67 Million USD | 67.394% |
| Genus plc | 485 Million USD | 98.207% |
| Pharming Group N.V. | 244.07 Million USD | 96.436% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -332.708% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -245.662% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -128.895% |
| ContraFect Corporation | 32.53 Million USD | 73.262% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -127.241% |
| IMV Inc. | 37.93 Million USD | 77.07% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 26.152% |
| ONE Bio Corp. | 27.49 Million USD | 68.366% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 88.765% |
| Mesoblast Limited | 188.44 Million USD | 95.384% |
| MultiCell Technologies, Inc. | 1617.67 USD | -537586.92% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 89.512% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.344% |
| Neon Bloom, Inc. | 1.22 Million USD | -609.338% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -69.023% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 9.226% |
| Biomind Labs Inc. | 1.49 Million USD | -480.404% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 3.807% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 52.737% |
| Skye Bioscience, Inc. | 14.07 Million USD | 38.19% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -506.614% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -48.872% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -6021.257% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -339.003% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 8.112% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -4224.867% |
| Accustem Sciences Inc. | 1.07 Million USD | -705.938% |
| EV Biologics, Inc. | 2.11 Million USD | -311.24% |
| Q BioMed Inc. | 8.13 Million USD | -6.948% |
| GB Sciences, Inc. | 5.41 Million USD | -60.552% |
| Alpha Cognition Inc. | 7.16 Million USD | -21.4% |
| CSL Limited | 18.62 Billion USD | 99.953% |
| Agentix Corp. | 2.51 Million USD | -246.457% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 92.674% |
| Enzolytics Inc. | 365.26 Million USD | 97.619% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | 87.094% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -937.042% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -51.38% |
| argenx SE | 444.95 Million USD | 98.045% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 88.39% |
| HST Global, Inc. | 593.59 Thousand USD | -1365.314% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -407.468% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -590.76% |
| Halberd Corporation | 728.71 Thousand USD | -1093.601% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 64.851% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -137.315% |
| Zenith Capital Corp. | 27.56 Thousand USD | -31449.929% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 26.927% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -132.921% |
| AVAX Technologies, Inc. | 3.99 Million USD | -117.791% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1177.551% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -220.765% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3544.607% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -10.651% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -12895.861% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 82.695% |
| Kadimastem Ltd | 3.5 Million USD | -148.169% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 45.312% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1771.749% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -31606.339% |
| LadRx Corporation | 2.2 Million USD | -295.269% |
| Cell Source, Inc. | 15.8 Million USD | 44.973% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -19360.354% |
| Regen BioPharma, Inc. | 5.45 Million USD | -59.374% |
| Regen BioPharma, Inc. | 5.45 Million USD | -59.374% |
| Affymax, Inc. | 8.87 Million USD | 1.95% |
| Mobile Lads Corp. | 1.31 Million USD | -562.202% |
| Itoco Inc. | 1.65 Million USD | -426.147% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -323.969% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -43.792% |
| International Stem Cell Corporation | 5.27 Million USD | -64.829% |
| CytoDyn Inc. | 127.89 Million USD | 93.199% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -20709.11% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -455.294% |
| Qrons Inc. | 1.48 Million USD | -484.263% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 21.251% |
| SYBLEU INC | 681.41 Thousand USD | -1176.465% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -975.428% |
| Rebus Holdings, Inc. | 5.24 Million USD | -65.929% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -42.546% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1289.881% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -88.386% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 78.783% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 60.934% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -329.449% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -58.781% |
| Neutra Corp. | 973.52 Thousand USD | -793.451% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 70.022% |
| PureTech Health plc | 125.58 Million USD | 93.074% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -131.507% |
| IXICO plc | 1.9 Million USD | -357.719% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 57.631% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 91.582% |
| CSL Limited | 18.62 Billion USD | 99.953% |
| Cellectis S.A. | 249.36 Million USD | 96.512% |